References
- Richard A, Larson M. Patient education: acute myeloid leukemia (AML) treatment in adults (beyond the basics). Waltham, MA, USA: Wolters Kluwer; 2016; Available at: http://www.uptodate.com/contents/acute-myeloid-leukemia-aml-treatment-in-adults-beyond-the-basics [Last accessed September 28, 2016]
- Deschler B, Lubbert M. Acute myeloid leukemia: epidemiology and etiology. Cancer 2006;107:2099-107
- American Cancer Society: Cancer facts and figures 2017. Atlanta, GA: American Cancer Society; 2017. Available at: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2017/cancer-facts-and-figures-2017.pdf [Last accessed February 2, 2018]
- Karen Seiter M. Acute myeloid leukemia treatment protocols. New York, NY, USA: Medscape, LLC; 2016. Available at: http://emedicine.medscape.com/article/2004793-overview [Last accessed September 28, 2016]
- Katz LM, Howell JB, Doyle JJ, et al. Outcomes and charges of elderly patients with acute myeloid leukemia. Am J Hematol 2006;81:850-7
- Meyers J, Yu Y, Kaye JA, et al. Medicare fee-for-service enrollees with primary acute myeloid leukemia: an analysis of treatment survival, and healthcare resource utilization and costs. Appl Health Econ Health Policy 2013;11:275-86
- Medeiros BC, Satram-Hoang S, Hurst D, et al. Big data analysis of treatment patterns and outcomes among elderly acute myeloid leukemia patients in the United States. Ann Hematol 2015;94:1127-38
- Irish W, Ryan M, Gache L, et al. Acute myeloid leukemia: a retrospective claims analysis of resource utilization and expenditures for newly diagnosed patients from first-line induction to remission and relapse. Curr Med Res Opin 2017;33:519-27
- Medeiros BC, Pandya BJ, Chen CC, et al. Economic burden of treatment episodes in acute myeloid leukemia (AML) patients in the US: a retrospective analysis of a commercial payer database. Presented at the 59th Annual American Society for Hematology Meeting & Exposition; December 9-12, 2017; Atlanta, GA, USA. Available at: https://ash.confex.com/ash/2017/webprogram/Paper106052.html [Last accessed February 7, 2018]
- Bell JA, Galaznik A, Farrelly E, et al. Treatment characteristics and outcomes for newly diagnosed elderly patients with acute myeloid leukemia (AML) treated in the United States with either 7 + 3 or a Hypomethylating agent (HMA). Presented at the 59th Annual American Society for Hematology Meeting & Exposition; December 9-12, 2017; Atlanta, GA, USA. Available at: https://ash.confex.com/ash/2017/webprogram/Paper106076.html [Last accessed February 7, 2018]
- Bell JA, Galaznik A, Farrelly E, et al. Healthcare costs in elderly patients with acute myeloid leukemia in routine clinical care in the United States. Presented at the 59th Annual American Society for Hematology Meeting & Exposition; December 9-12, 2017; Atlanta, GA, USA. Available at: https://ash.confex.com/ash/2017/webprogram/Paper105965.html [Last accessed February 7, 2018]
- Stein EM, Bonifacio G, Letremouille-Viau D, et al. Treatment patterns, healthcare resource utilization, and costs in patients with acute myeloid leukemia in commercially insured and Medicare populations. J Med Econ 2018;21:556-63
- FDA News Release. FDA approves first treatment for certain types of poor-prognosis acute myeloid leukemia. Silver Spring, MD, USA; 2017. Available at: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm569883.html [Last accessed February 7, 2018]
- IMS Health, IMS LifeLink. PharMetrics Health Data Dictionary. Danbury, CT, USA; January 2013
- Sorror ML. Comorbidities and hematopoietic cell transplantation outcomes. Hematology Am Soc Hematol Educ Program 2010;2010:237-47
- National Cancer Institute, Division of Cancer Control & Population Sciences. NCI Comorbidity Index Overview. Rockville, MD, USA; 2014. Available at: https://healthcaredelivery.cancer.gov/seermedicare/considerations/comorbidity.html [Last accessed September 28, 2016]